Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System

Apostolidou, Effrosyni; Lachowiez, Curtis; Juneja, Harinder S.; Qiao, Wei; Ononogbu, Onyebuchi; Miller-Chism, Courtney Nicole; Udden, Mark M.; Ma, Huaxian; Mims, Martha P.

doi:10.1016/j.clml.2021.06.022

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A limitation of Blinotumamab 7 and other non-IgG-like bispecifics 8,9 is that these molecules lack fragment crystallizable domains and have short halflives, which necessitate continuous high dose intravenous infusions. Moreover, this intensive regimen can be challenging for patients, especially those with limited hospital access 10,11 . A range of methods have been utilized in an attempt to extend biologic half-life of non-IgG-like bispecifics 12 , including conjugation with small molecules, fragment crystallizable domains, or albumin binding motifs.…”

Section: Introductionmentioning

confidence: 99%

Human plasma cells engineered to secrete bispecifics drive effectivein vivoleukemia killing

Hill,

Narvekar,

Asher

et al. 2023

Preprint

View full text Add to dashboard Cite

Bispecific antibodies are an important tool for the management and treatment of acute leukemias. Advances in genome-engineering have enabled the generation of human plasma cells that secrete therapeutic proteins and are capable of long-termin vivoengraftment in humanized mouse models. As a next step towards clinical translation of engineered plasma cells (ePCs) towards cancer therapy, here we describe approaches for the expression and secretion of bispecific antibodies by human plasma cells. We show that human ePCs expressing either fragment crystallizable domain deficient anti-CD19 x anti-CD3 (blinatumomab) or anti-CD33 x anti-CD3 bispecific antibodies mediate T cell activation and direct T cell killing of specific primary human cell subsets and B-acute lymphoblastic leukemia or acute myeloid leukemia cell linesin vitro. We demonstrate that knockout of the self-expressed antigen, CD19, boosts anti-CD19 bispecific secretion by ePCs and prevents self-targeting. Further, anti-CD19 bispecific-ePCs elicited tumor eradicationin vivofollowing local delivery in flank-implanted Raji lymphoma cells. Finally, immunodeficient mice engrafted with anti-CD19 bispecific-ePCs and autologous T cells potently preventedin vivogrowth of CD19+acute lymphoblastic leukemia in patient-derived xenografts. Collectively, these findings support further development of ePCs for use as a durable, local delivery system for the treatment of acute leukemias, and potentially other cancers.Key pointsUsing gene editing, we engineered human plasma cells that secrete functional bispecifics to target leukemia cells expressing CD19 or CD33Engineered plasma cells secreting bispecifics suppress patient-derived leukemia in immunodeficient mice

show abstract